Video
Dr. Bekaii-Saab on the Importance of the ReDOS Study in mCRC
Author(s):
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the importance of the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer (mCRC).
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the importance of the phase II regorafenib (Stivarga) dose-optimization study (ReDOS) in metastatic colorectal cancer (mCRC).
The study randomized patients with mCRC to either the dose-escalation arm, which began at 80 mg per day and increased weekly up to 160 mg per day if no significant drug-related toxicities occurred, or the standard dose of 160 mg of regorafenib daily. This is now a preferred option of how to administer regorafenib, explains Bekaii-Saab.
According to Bekaii-Saab, there is now a strategy for physicians who are reluctant to start with 160 mg. Rather than doing guesswork, there is now a strategy that demonstrates that there is no loss in benefit by starting with a lower dose and escalating to 120 mg or 160 mg.
